Navigating Potency Assay Strategy: From IND to BLA Compliance

In the competitive landscape of biologics development, the potency assay is more than just a quality control metric—it is a critical demonstration of your drug's mechanism of action (MOA). As your therapeutic candidate moves through the clinical pipeline, the regulatory expectations for how you define and measure that potency evolve significantly.

For sponsors, the transition from Phase I to BLA requires a robust strategy that ensures your potency assay validation keeps pace with clinical milestones. Failure to plan for this evolution can lead to costly delays during the regulatory review process.

The Evolution of Potency: From Early Development to Commercialization

The journey of potency testing is defined by an increase in precision and regulatory rigor.

• Phase I: Initial Characterization At the IND-enabling stage, the primary goal is to establish a bridge between your candidate's activity and its clinical effect. Early-stage IND-enabling studies often utilize exploratory or functional assays. While these do not require full validation, they must demonstrate consistency and relevance to the drug's intended therapeutic effect.
• Phase II: Method Optimization and Refinement As you gather clinical data, your assay must be refined to support dose-ranging studies. This is the stage to identify critical quality attributes (CQAs) and begin formalizing the assay parameters.
• Phase III and BLA: Rigorous Validation By the time you approach a Biologics License Application (BLA), your assay must be fully validated according to FDA CBER guidelines. Regulators expect a well-characterized method that provides quantitative, reproducible results, capable of serving as the release and stability testing standard.

Aligning with Regulatory Expectations

Regulatory agencies, particularly under FDA CBER guidelines, mandate that the potency assay reflects the drug's biological activity as closely as possible. As your product matures, you must transition from descriptive qualitative assays to quantitative methods that characterize the relative potency against a reference standard.

Developing these methods requires deep expertise in analytical chemistry and biology. At Alfa Chemistry, we provide specialized potency testing services designed to support your program through every stage of development. Whether you are performing early-stage functional assays or final method validation for BLA submission, our laboratory offers the technical rigor and regulatory insight required to accelerate your path to market.

Conclusion

A proactive approach to your potency strategy is essential for mitigating clinical and regulatory risks. By aligning your analytical methods with the clinical stage and maintaining a clear link to the MOA, you ensure that your drug product consistently meets safety and efficacy benchmarks.

Frequently Asked Questions (FAQ)

Alfa Chemistry is a professional analytical testing company, and has long been committed to promoting the long-term development of the analytical testing industry. We sincerely welcome colleagues from all walks of life to come to negotiate and cooperate.